Floshin Introduces DeFi Products, Converges with Cross-Chain and Initiates Airdrop
London, United Kingdom–(Newsfile Corp. – February 23, 2022) – Floshin brings forward a suite of…
London, United Kingdom–(Newsfile Corp. – February 23, 2022) – Floshin brings forward a suite of…
Internet City, Dubai–(Newsfile Corp. – February 23, 2022) – ZEXPRWIRE, LBank Exchange, a global digital…
Internet City, Dubai–(Newsfile Corp. – February 23, 2022) – LBank Exchange, a global digital asset…
Strongest Slate To Date Features New and Returning Series Favorites Plus Feature Films Including DOUG…
SAN FRANCISCO & TEL AVIV, Israel–(BUSINESS WIRE)–Varos, a data sharing platform helping companies compare their…
New Threat Lens application delivers strategic and tactical threat intelligence across a range of risk…
AUSTIN, Texas, Feb. 23, 2022 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical…
Management to host conference call and webcast at 4:30 pm ET on that day Boca…
Award-winning California cannabis company tops more than 500 statewide competitors in sales, led by premier…
Genomics Industry Veteran to Oversee Development of Robust Computational Biology Program MENLO PARK, Calif., Feb….
NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused…
VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) — via InvestorWire – AREV Life Sciences…
SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”)…
BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company…
CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage…
BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
Panel to take place on Monday, February 28, 2022, at 2:55pm EST / 11:55am PST…
Collaboration to identify patient-selection biomarkers for Cyclerion’s investigational therapeutics in neurological and neuropsychiatric diseases associated…
— INNA-051 is being developed to stimulate innate immunity and reduce the incidence and severity…
Best corrected visual acuity and central subfield thickness were significantly improved at 36 months ILUVIEN…